{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:53:54Z","timestamp":1792068834834,"version":"4.4.0"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AI168165"],"award-info":[{"award-number":["R01AI168165"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic &amp; Medicinal Chemistry"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.bmc.2026.118792","type":"journal-article","created":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T23:15:59Z","timestamp":1788045359000},"page":"118792","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Discovery of SARS-CoV-2 PLpro covalent inhibitors enabled by a novel reversible covalent chloroalkyne warhead"],"prefix":"10.1016","volume":"143","author":[{"given":"Divakar","family":"Indukuri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jazmin Galv\u00e1n","family":"Achi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boopathi","family":"Sownthirarajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malla Reddy","family":"Gannarapu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar Lozano","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiira","family":"Ratia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyajit","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rishi Vardhan","family":"Chunduru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuohuang","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulina","family":"Anguiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balaji","family":"Manicassamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijun","family":"Rong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"15","key":"10.1016\/j.bmc.2026.118792_bb0005","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25158155","article-title":"Comprehensive review of COVID-19: epidemiology, pathogenesis, advancement in diagnostic and detection techniques, and post-pandemic treatment strategies","volume":"25","author":"Chung","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"15","key":"10.1016\/j.bmc.2026.118792_bb0010","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2026.31.15.2500672","article-title":"Clinical and economic benefits of seasonal COVID-19 vaccination in Germany: results from the ROUTINE-COV19 Study, September 2022 to March 2024","volume":"31","author":"Schmetz","year":"2026","journal-title":"Euro Surveill."},{"issue":"6575","key":"10.1016\/j.bmc.2026.118792_bb0015","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1126\/science.abl4784","article-title":"An oral SARS-CoV-2 M(pro) inhibitor clinical candidate for the treatment of COVID-19","volume":"374","author":"Owen","year":"2021","journal-title":"Science"},{"issue":"10339","key":"10.1016\/j.bmc.2026.118792_bb0020","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1016\/S0140-6736(22)00519-0","article-title":"Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO solidarity randomised trial and updated meta-analyses","volume":"399","year":"2022","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.bmc.2026.118792_bb0025","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJMoa2116044","article-title":"Molnupiravir for oral treatment of COVID-19 in nonhospitalized patients","volume":"386","author":"Bernal","year":"2022","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.bmc.2026.118792_bb0030","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1001\/jamainternmed.2023.0743","article-title":"Association of Treatment with Nirmatrelvir and the risk of post\u2013COVID-19 condition","volume":"183","author":"Xie","year":"2023","journal-title":"JAMA Intern Med"},{"issue":"6","key":"10.1016\/j.bmc.2026.118792_bb0035","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/s41579-023-00878-2","article-title":"The evolution of SARS-CoV-2","volume":"21","author":"Markov","year":"2023","journal-title":"Nat Rev Microbiol"},{"issue":"42","key":"10.1016\/j.bmc.2026.118792_bb0040","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abd4596","article-title":"Activity profiling and crystal structures of inhibitor-bound SARS-CoV-2 papain-like protease: a framework for anti-COVID-19 drug design","volume":"6","author":"Rut","year":"2020","journal-title":"Sci Adv"},{"issue":"1","key":"10.1016\/j.bmc.2026.118792_bb0045","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1038\/s41467-023-38031-5","article-title":"Dual domain recognition determines SARS-CoV-2 PLpro selectivity for human ISG15 and K48-linked di-ubiquitin","volume":"14","author":"Wydorski","year":"2023","journal-title":"Nat Commun"},{"issue":"7835","key":"10.1016\/j.bmc.2026.118792_bb0050","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41586-020-2601-5","article-title":"Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity","volume":"587","author":"Shin","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.bmc.2026.118792_bb0055","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.77433","article-title":"Comprehensive fitness landscape of SARS-CoV-2 Mpro reveals insights into viral resistance mechanisms","volume":"11","author":"Flynn","year":"2022","journal-title":"eLife"},{"issue":"1","key":"10.1016\/j.bmc.2026.118792_bb0060","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/s12967-023-03996-w","article-title":"Global landscape of SARS-CoV-2 mutations and conserved regions","volume":"21","author":"Abbasian","year":"2023","journal-title":"J Transl Med"},{"issue":"42","key":"10.1016\/j.bmc.2026.118792_bb0065","doi-asserted-by":"crossref","first-page":"16119","DOI":"10.1073\/pnas.0805240105","article-title":"A noncovalent class of papain-like protease\/deubiquitinase inhibitors blocks SARS virus replication","volume":"105","author":"Ratia","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"10.1016\/j.bmc.2026.118792_bb0070","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1021\/acs.jmedchem.1c01307","article-title":"Design of SARS-CoV-2 PLpro inhibitors for COVID-19 antiviral therapy leveraging binding cooperativity","volume":"65","author":"Shen","year":"2022","journal-title":"J Med Chem"},{"issue":"16","key":"10.1016\/j.bmc.2026.118792_bb0075","doi-asserted-by":"crossref","first-page":"13681","DOI":"10.1021\/acs.jmedchem.4c00378","article-title":"Non-covalent inhibitors of SARS-CoV-2 papain-like protease (PLpro): in vitro and in vivo antiviral activity","volume":"67","author":"Velma","year":"2024","journal-title":"J Med Chem"},{"issue":"6690","key":"10.1016\/j.bmc.2026.118792_bb0080","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1126\/science.adm9724","article-title":"Design of a SARS-CoV-2 papain-like protease inhibitor with antiviral efficacy in a mouse model","volume":"383","author":"Tan","year":"2024","journal-title":"Science"},{"issue":"35","key":"10.1016\/j.bmc.2026.118792_bb0085","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.ado4288","article-title":"Discovery of SARS-CoV-2 papain-like protease (PL<sup>pro<\/sup>) inhibitors with efficacy in a murine infection model","volume":"10","author":"Garnsey","year":"2024","journal-title":"Sci Adv"},{"issue":"7","key":"10.1016\/j.bmc.2026.118792_bb0090","doi-asserted-by":"crossref","first-page":"8433","DOI":"10.1021\/acs.jmedchem.5c03846","article-title":"Discovery of the SARS-CoV-2 papain-like protease inhibitor MR1\u2013114: from structure-based design to in vivo antiviral efficacy","volume":"69","author":"Gannarapu","year":"2026","journal-title":"J Med Chem"},{"issue":"1","key":"10.1016\/j.bmc.2026.118792_bb0095","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1038\/s41467-025-57905-4","article-title":"A novel PLpro inhibitor improves outcomes in a pre-clinical model of long COVID","volume":"16","author":"Bader S","year":"2025","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.bmc.2026.118792_bb0100","doi-asserted-by":"crossref","first-page":"10169","DOI":"10.1038\/s41467-024-54462-0","article-title":"Discovery of orally bioavailable SARS-CoV-2 papain-like protease inhibitor as a potential treatment for COVID-19","volume":"15","author":"Lu","year":"2024","journal-title":"Nat Commun"},{"issue":"11","key":"10.1016\/j.bmc.2026.118792_bb0105","doi-asserted-by":"crossref","first-page":"7561","DOI":"10.1021\/acs.jmedchem.2c00303","article-title":"Progress and challenges in targeting the SARS-CoV-2 papain-like protease","volume":"65","author":"Tan","year":"2022","journal-title":"J Med Chem"},{"issue":"19","key":"10.1016\/j.bmc.2026.118792_bb0110","doi-asserted-by":"crossref","DOI":"10.1002\/cbic.202200327","article-title":"SARS-CoV-2 papain-like protease: structure, function and inhibition","volume":"23","author":"Ullrich","year":"2022","journal-title":"Chembiochem"},{"key":"10.1016\/j.bmc.2026.118792_bb0115","article-title":"Potential inhibitors targeting papain-like protease of SARS-CoV-2: two birds with one stone","volume":"10\u20132022","author":"Jiang","year":"2022","journal-title":"Front Chem"},{"issue":"11","key":"10.1016\/j.bmc.2026.118792_bb0120","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1002\/cmdc.202000223","article-title":"Drug development and medicinal chemistry efforts toward SARS-coronavirus and Covid-19 therapeutics","volume":"15","author":"Ghosh","year":"2020","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bmc.2026.118792_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114572","article-title":"Chalcone-amide, a privileged backbone for the design and development of selective SARS-CoV\/SARS-CoV-2 papain-like protease inhibitors","volume":"240","author":"Valipour","year":"2022","journal-title":"Eur J Med Chem"},{"issue":"52","key":"10.1016\/j.bmc.2026.118792_bb0130","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202212378","article-title":"Identification of cysteine 270 as a novel site for allosteric modulators of SARS-CoV-2 papain-like protease","volume":"61","author":"Hu","year":"2022","journal-title":"Angew Chem Int Ed"},{"key":"10.1016\/j.bmc.2026.118792_bb0135","article-title":"Structure-based design of potent peptidomimetic inhibitors covalently targeting SARS-CoV-2 papain-like protease","volume":"24","author":"Wang","year":"2023","journal-title":"Int J Mol Sci."},{"key":"10.1016\/j.bmc.2026.118792_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmcr.2025.100306","article-title":"Design, synthesis, and binding analysis of target-specific covalent inhibitors of SARS-CoV-2 papain-like protease","volume":"15","author":"Bagdonas","year":"2025","journal-title":"European Journal of Medicinal Chemistry Reports"},{"key":"10.1016\/j.bmc.2026.118792_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2025.141730","article-title":"Review of the crystallized structures of the SARS-CoV-2 papain-like protease","volume":"1333","author":"Yue","year":"2025","journal-title":"J Mol Struct"},{"issue":"1","key":"10.1016\/j.bmc.2026.118792_bb0150","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1038\/s41467-025-56902-x","article-title":"Design of quinoline SARS-CoV-2 papain-like protease inhibitors as oral antiviral drug candidates","volume":"16","author":"Jadhav","year":"2025","journal-title":"Nat Commun"},{"issue":"40","key":"10.1016\/j.bmc.2026.118792_bb0155","doi-asserted-by":"crossref","first-page":"47165","DOI":"10.1021\/acsomega.5c05856","article-title":"SARS-CoV-2 papain-like protease inhibitors based on Naphthalen-1-ylethanamine and halogenated benzene moieties","volume":"10","author":"Shinohara","year":"2025","journal-title":"ACS Omega"},{"issue":"7","key":"10.1016\/j.bmc.2026.118792_bb0160","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/nchembio.1817","article-title":"Prolonged and tunable residence time using reversible covalent kinase inhibitors","volume":"11","author":"Bradshaw","year":"2015","journal-title":"Nat Chem Biol"},{"issue":"4","key":"10.1016\/j.bmc.2026.118792_bb0165","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1080\/17568919.2025.2453407","article-title":"Key advances in the development of reversible covalent inhibitors","volume":"17","author":"Faridoon","year":"2025","journal-title":"Future Med Chem"},{"issue":"1","key":"10.1016\/j.bmc.2026.118792_bb0170","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.apsb.2023.08.004","article-title":"Medicinal chemistry strategies towards the development of non-covalent SARS-CoV-2 Mpro inhibitors","volume":"14","author":"Song","year":"2024","journal-title":"Acta Pharm Sin B"},{"issue":"23","key":"10.1016\/j.bmc.2026.118792_bb0175","doi-asserted-by":"crossref","first-page":"10497","DOI":"10.1021\/acs.jmedchem.9b00683","article-title":"Can cysteine protease cross-class inhibitors achieve selectivity?","volume":"62","author":"Cianni","year":"2019","journal-title":"J Med Chem"},{"issue":"1","key":"10.1016\/j.bmc.2026.118792_bb0180","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-37254-w","article-title":"Potent and selective covalent inhibition of the papain-like protease from SARS-CoV-2","volume":"14","author":"Sanders","year":"2023","journal-title":"Nat Commun"},{"issue":"22","key":"10.1016\/j.bmc.2026.118792_bb0185","doi-asserted-by":"crossref","first-page":"20399","DOI":"10.1021\/acs.jmedchem.4c01872","article-title":"Structure-based Design of Covalent SARS-CoV-2 papain-like protease inhibitors","volume":"67","author":"Tan","year":"2024","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118792_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2024.130034","article-title":"Synthesis and structure-activity relationship of covalent inhibitors of SARS-CoV-2 papain-like protease with antiviral potency","volume":"116","author":"Rouch","year":"2025","journal-title":"Bioorg Med Chem Lett"},{"issue":"11","key":"10.1016\/j.bmc.2026.118792_bb0195","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1021\/acsmedchemlett.5c00482","article-title":"Targeting the S1\u2032 pocket of SARS-CoV-2 papain-like protease yields highly potent inhibitors","volume":"16","author":"Garad","year":"2025","journal-title":"ACS Med Chem Lett"},{"issue":"3","key":"10.1016\/j.bmc.2026.118792_bb0200","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1021\/acs.jmedchem.5c01973","article-title":"Structure-guided Design of Potent and Selective Covalent Inhibitors Targeting the SARS-CoV-2 papain-like protease","volume":"69","author":"Sharafi","year":"2026","journal-title":"J Med Chem"},{"issue":"18","key":"10.1016\/j.bmc.2026.118792_bb0205","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2020106275","article-title":"Mechanism and inhibition of the papain-like protease, PLpro, of SARS-CoV-2","volume":"39","author":"Klemm","year":"2020","journal-title":"EMBO J"},{"issue":"30","key":"10.1016\/j.bmc.2026.118792_bb0210","doi-asserted-by":"crossref","first-page":"E6231","DOI":"10.1073\/pnas.1701848114","article-title":"Prediction of intracellular exposure bridges the gap between target- and cell-based drug discovery","volume":"114","author":"Mateus","year":"2017","journal-title":"Proc Natl Acad Sci"},{"issue":"4","key":"10.1016\/j.bmc.2026.118792_bb0215","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1124\/dmd.112.050054","article-title":"Lysosomal sequestration (trapping) of lipophilic amine (cationic amphiphilic) drugs in immortalized human hepatocytes (Fa2N-4 cells)","volume":"41","author":"Kazmi","year":"2013","journal-title":"Drug Metab Dispos"},{"issue":"9","key":"10.1016\/j.bmc.2026.118792_bb0220","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.1002\/jps.23614","article-title":"Plasma protein binding: from discovery to development","volume":"102","author":"Bohnert","year":"2013","journal-title":"J Pharm Sci"},{"issue":"13","key":"10.1016\/j.bmc.2026.118792_bb0225","doi-asserted-by":"crossref","first-page":"6679","DOI":"10.1021\/acs.jmedchem.9b02052","article-title":"Identification of the clinical development candidate MRTX849, a covalent KRASG12C inhibitor for the treatment of Cancer","volume":"63","author":"Fell","year":"2020","journal-title":"J Med Chem"},{"issue":"8","key":"10.1016\/j.bmc.2026.118792_bb0230","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.1021\/jacs.8b11027","article-title":"The alkyne moiety as a latent electrophile in irreversible covalent small molecule inhibitors of Cathepsin K","volume":"141","author":"Mons","year":"2019","journal-title":"J Am Chem Soc"},{"issue":"36","key":"10.1016\/j.bmc.2026.118792_bb0235","doi-asserted-by":"crossref","first-page":"12624","DOI":"10.1021\/ja505194w","article-title":"Design of Reversible, cysteine-targeted Michael acceptors guided by kinetic and computational analysis","volume":"136","author":"Krishnan","year":"2014","journal-title":"J Am Chem Soc"},{"issue":"1","key":"10.1016\/j.bmc.2026.118792_bb0240","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1070\/RC1974v043n01ABEH001786","article-title":"Equilibrium acidity of carbon\u2013hydrogen bonds in organic compounds","volume":"43","author":"Oleg","year":"1974","journal-title":"Russ Chem Rev"},{"key":"10.1016\/j.bmc.2026.118792_bb0245","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3762\/bjoc.22.1","article-title":"Synthesis and applications of alkenyl chlorides (vinyl chlorides): a review","volume":"22","author":"M\u00fcller","year":"2026","journal-title":"Beilstein J Org Chem"},{"issue":"11","key":"10.1016\/j.bmc.2026.118792_bb0250","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1021\/ed070p873","article-title":"The electrophilic addition to alkynes","volume":"70","author":"Weiss","year":"1993","journal-title":"J Chem Educ"},{"key":"10.1016\/j.bmc.2026.118792_bb0255","article-title":"Cysteine protease inhibition by nitrile-based inhibitors: a computational study","volume":"1\u20132013","author":"De Visser","year":"2013","journal-title":"Front Chem"},{"issue":"1","key":"10.1016\/j.bmc.2026.118792_bb0260","article-title":"Factors affecting irreversible inhibition of EGFR and influence of chirality on covalent binding","volume":"8","author":"Morese","year":"2025","journal-title":"Commun Chem"},{"issue":"8016","key":"10.1016\/j.bmc.2026.118792_bb0265","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41586-024-07487-w","article-title":"Accurate structure prediction of biomolecular interactions with AlphaFold 3","volume":"630","author":"Abramson","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.bmc.2026.118792_bb0270","first-page":"43","article-title":"Scalable Algorithms for Molecular Dynamics Simulations on Commodity Clusters, in: SC \u201906: Proceedings of the 2006","author":"Bowers","year":"2026","journal-title":"ACM\/IEEE Conference on Supercomputing, p"}],"container-title":["Bioorganic &amp; Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089626002488?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089626002488?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:34:50Z","timestamp":1792067690000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089626002488"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":54,"alternative-id":["S0968089626002488"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2026.118792","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of SARS-CoV-2 PLpro covalent inhibitors enabled by a novel reversible covalent chloroalkyne warhead","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2026.118792","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118792"}}